Regeneron Pharmaceuticals Patent-Cliff Exposure & CMS Drug Spending Portfolio

Regeneron Pharmaceuticals (Tarrytown, NY): 9 reconciled FDA prescription therapies, $5.74B 2024 CMS Part D & Medicaid spend, and 15 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterTarrytown, NY
Reconciled FDA Portfolio Therapies9
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$5.74B
2024 Medicare Part D Spend$2.94B
2024 Medicaid Spend$2.81B
California HCAI SB 17 Filings15 WAC filings (max 18.7% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Regeneron Pharmaceuticals across sibling Meru public-data platforms.